These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16404496)

  • 1. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab.
    Gutiérrez-Macías A; Lizarralde-Palacios E; Martínez-Odriozola P; Miguel-de la Villa F
    Clin Rheumatol; 2007 Mar; 26(3):452-3. PubMed ID: 16404496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculous peritonitis after treatment with adalimumab.
    Antolín J; Azahara M; Hernández C; Blanco M; Mao L; Cigüenza R
    Scand J Infect Dis; 2008; 40(8):677-8. PubMed ID: 18979608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab.
    Azevedo VF; Parchen C; Coelho SA; Lacerda DC; Hirth CG
    Rheumatol Int; 2009 Sep; 29(11):1381-4. PubMed ID: 19142641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of tuberculous peritonitis in the United States in a patient with rheumatoid arthritis treated with adalimumab.
    Szeto T; Peterson J; Silva F
    J Clin Rheumatol; 2010 Apr; 16(3):135-7. PubMed ID: 20375825
    [No Abstract]   [Full Text] [Related]  

  • 5. Adalimumab desensitization after anaphylactic reaction.
    Quercia O; Emiliani F; Foschi FG; Stefanini GF
    Ann Allergy Asthma Immunol; 2011 Jun; 106(6):547-8. PubMed ID: 21624763
    [No Abstract]   [Full Text] [Related]  

  • 6. Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment.
    Efde MN; Houtman PM; Spoorenberg JP; Jansen TL
    Neth J Med; 2005 Mar; 63(3):112-4. PubMed ID: 15813424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appearance of rheumatoid nodules following anti-tumor necrosis factor alpha treatment with adalimumab for rheumatoid arthritis.
    Scrivo R; Spadaro A; Iagnocco A; Valesini G
    Clin Exp Rheumatol; 2007; 25(1):117. PubMed ID: 17418005
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pulmonary tuberculosis associated to adalimumab: a study of 3 cases].
    Blanco Pérez JJ; Aranda Torres A; Pego Reigosa JM; Núñez Delgado M; Temes Montes E; Guerra Vales JL
    Arch Bronconeumol; 2010 Apr; 46(4):203-5. PubMed ID: 19896259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alopecia areata following adalimumab.
    Kirshen C; Kanigsberg N
    J Cutan Med Surg; 2009; 13(1):48-50. PubMed ID: 19298772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis.
    van Eijk IC; Peters MJ; Nurmohamed MT; van Deutekom AW; Dijkmans BA; Simsek S
    Eur J Endocrinol; 2007 Mar; 156(3):291-3. PubMed ID: 17322487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab.
    Kurmann PT; Van Linthoudt D; So AK
    Clin Rheumatol; 2009 Jan; 28(1):93-4. PubMed ID: 18818868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocardia infection with adalimumab in rheumatoid arthritis.
    Doraiswamy VA
    J Rheumatol; 2008 Mar; 35(3):542-3. PubMed ID: 18322980
    [No Abstract]   [Full Text] [Related]  

  • 13. Membranous nephropathy in rheumatoid arthritis: a case report.
    Maruotti N; Corrado A; Gaudio A; Cantatore FP
    Clin Exp Rheumatol; 2009; 27(5):840-2. PubMed ID: 19917171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab.
    Kalyoncu U; Karadag O; Akdogan A; Kisacik B; Erman M; Erguven S; Ertenli AI
    Scand J Infect Dis; 2007; 39(5):475-8. PubMed ID: 17464877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 20. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.